- Home
- PDSB vs HLVX Comparison
PDSB vs HLVX Comparison
Compare PDSB & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDSB
- HLVX
- Stock Information
- Founded
- PDSB 2005
- HLVX 2020
- Country
- PDSB United States
- HLVX United States
- Employees
- PDSB N/A
- HLVX N/A
- Industry
- PDSB Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- PDSB Health Care
- HLVX Health Care
- Exchange
- PDSB Nasdaq
- HLVX Nasdaq
- Market Cap
- PDSB 72.2M
- HLVX 83.7M
- IPO Year
- PDSB N/A
- HLVX 2022
- Fundamental
- Price
- PDSB $1.19
- HLVX $2.06
- Analyst Decision
- PDSB Strong Buy
- HLVX Hold
- Analyst Count
- PDSB 2
- HLVX 1
- Target Price
- PDSB $10.00
- HLVX $2.00
- AVG Volume (30 Days)
- PDSB 544.6K
- HLVX 386.3K
- Earning Date
- PDSB 08-12-2025
- HLVX 08-07-2025
- Dividend Yield
- PDSB N/A
- HLVX N/A
- EPS Growth
- PDSB N/A
- HLVX N/A
- EPS
- PDSB N/A
- HLVX N/A
- Revenue
- PDSB N/A
- HLVX N/A
- Revenue This Year
- PDSB N/A
- HLVX N/A
- Revenue Next Year
- PDSB N/A
- HLVX N/A
- P/E Ratio
- PDSB N/A
- HLVX N/A
- Revenue Growth
- PDSB N/A
- HLVX N/A
- 52 Week Low
- PDSB $0.85
- HLVX $1.34
- 52 Week High
- PDSB $4.32
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- PDSB 39.96
- HLVX 53.77
- Support Level
- PDSB $1.02
- HLVX $2.09
- Resistance Level
- PDSB $1.28
- HLVX $2.17
- Average True Range (ATR)
- PDSB 0.11
- HLVX 0.08
- MACD
- PDSB -0.01
- HLVX 0.00
- Stochastic Oscillator
- PDSB 47.61
- HLVX 52.17
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.